Comment on - Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose: reply

Naja Emborg Vinding^*, Lars Køber, Emil Loldrup Fosbøl

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	European Heart Journal - Cardiovascular Pharmacotherapy
Vol/bind	7
Udgave nummer	1
Sider (fra-til)	75
Antal sider	1
ISSN	2055-6837
DOI	https://doi.org/10.1093/ehjcvp/pvaa023
Status	Udgivet - 2021

Adgang til dokumentet

@article{faeafcc18ec64d71b529decc21ee7b28,

title = "Comment on - Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose: reply",

author = "Vinding, {Naja Emborg} and Lars K{\o}ber and Fosb{\o}l, {Emil Loldrup}",

year = "2021",

doi = "10.1093/ehjcvp/pvaa023",

language = "English",

volume = "7",

pages = "75",

journal = "European Heart Journal - Cardiovascular Pharmacotherapy",

issn = "2055-6837",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Comment on - Switching from vitamin K antagonist to dabigatran in atrial fibrillation

T2 - differences according to dose: reply

AU - Vinding, Naja Emborg

AU - Køber, Lars

AU - Fosbøl, Emil Loldrup

PY - 2021

Y1 - 2021

U2 - 10.1093/ehjcvp/pvaa023

DO - 10.1093/ehjcvp/pvaa023

M3 - Comment/debate

C2 - 32240290

AN - SCOPUS:85100361711

SN - 2055-6837

VL - 7

SP - 75

JO - European Heart Journal - Cardiovascular Pharmacotherapy

JF - European Heart Journal - Cardiovascular Pharmacotherapy

IS - 1

ER -